Biochemical and pharmacological characterization of FR134043, a novel elastase inhibitor

被引:13
|
作者
Shinguh, Y [1 ]
Yamazaki, A [1 ]
Inamura, N [1 ]
Fujie, K [1 ]
Okamoto, M [1 ]
Nakahara, K [1 ]
Notsu, Y [1 ]
Okuhara, M [1 ]
Ono, T [1 ]
机构
[1] Fujisawa Pharmaceut Co Ltd, Exploratory Res Labs, Tsukuba, Ibaraki 30026, Japan
关键词
FR134043; elastase inhibitor; elastase; adult respiratory distress syndrome; disseminated intravascular coagulation; septic shock; pulmonary emphysema; hemorrhage; edema;
D O I
10.1016/S0014-2999(98)00028-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
FR 134043, disodium(Z1S,15S,18S,24S,27R,29S,34S,37R)-29-benzyl-21-ethylidene-27-hydroxy-15-isobutyrylamino-34-isopropyl-31,37-dimethyl-10,16,19,22,30,32,35,38-octaoxo-36-oxa-9,11,17,20,23,28,31,33-octaazatetracyclo[16.13.61(24, 28).0(3, 8)]octatriconta-3,5,7-trien-5,6-diyl disulfate, is a water-soluble inhibitor of human neutrophil elastase with a molecular mass of 1166.15 Da. FR134043 demonstrated a characteristic competitive inhibition of human neutrophil elastase with a K-i of 8 nM. In studies using synthetic substrates, FR134043 inhibited both neutrophil elastase activity and porcine pancreatic elastase activity with IC50 values of 35 nM and 49 nM respectively. FR134043 also inhibited hydrolysis of bovine neck ligament elastin by human neutrophil elastase with an IC50 value of 210 nM. In in vivo experiments, FR134043 protected animals against human neutrophil elastase (50 mu g/animal)-induced lung hemorrhage in hamsters with an ED50 value of 3.1 mu g/animal for intratracheal administration and 5.0 mg/kg for intravenous administration. Subcutaneous treatment with FR134043 significantly suppressed human neutrophil elastase (20 mu g/paw)-induced paw edema in mice with an ED50 value of 3.3 mg/kg when evaluated 4 h after elastase injection. The potency of FR134043 given intratracheally to protect against porcine pancreatic elastase (100 mu g/animal)-induced emphysema in hamsters was relatively low (Quasi-static lung compliance; ED50 = 1590 mu g/animal) compared to that in acute animal models. FR134043 (10 mg/kg per h i.v. infusion) significantly improved lipopolysaccharide (0.25 mg/kg per h i.v. infusion)-induced thrombocytopenia and some coagulation parameters in rats. These results suggest that systemic administration of FR134043 would be advantageous over intratracheal administration of FR134043 for the treatment of adult respiratory distress syndrome, septic shock and pulmonary emphysema and other pathophysiologic conditions in which elastases are thought to be involved. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:299 / 308
页数:10
相关论文
共 50 条
  • [1] Conformational study of FR134043, a novel inhibitor of human leukocyte elastase
    Fujikawa, A
    Nakanishi, I
    Sato, A
    Fujioka, M
    Yasuda, T
    PEPTIDE CHEMISTRY 1995, 1996, : 437 - 440
  • [2] Release of neutrophil elastase and its role in tissue injury in acute inflammation: effect of the elastase inhibitor, FR134043
    Fujie, K
    Shinguh, Y
    Inamura, N
    Yasumitsu, R
    Okamoto, M
    Okuhara, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 374 (01) : 117 - 125
  • [3] 1H-NMR determination of the solution structure and absolute configuration of FR134043, a novel inhibitor of human leukocyte elastase
    Nakanishi, I
    Fujikawa, A
    Imai, K
    Sato, A
    JOURNAL OF PEPTIDE RESEARCH, 2000, 55 (02): : 120 - 128
  • [4] Biochemical and pharmacological characterization of FK706, a novel elastase inhibitor
    Shinguh, Y
    Imai, K
    Yamazaki, A
    Inamura, N
    Shima, I
    Wakabayashi, A
    Higashi, Y
    Ono, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 337 (01) : 63 - 71
  • [5] Pharmacological characterization of a novel orally active neutrophil elastase inhibitor
    Kuromiya, A
    Okazaki, H
    Tsuji, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2691 - U2692
  • [6] BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF ICI 186,756 - A NOVEL, POTENT, AND SELECTIVE INHIBITOR OF HUMAN NEUTROPHIL ELASTASE
    WILLIAMS, JC
    STEIN, RL
    STRIMPLER, AM
    REAVES, B
    KRELL, RD
    EXPERIMENTAL LUNG RESEARCH, 1991, 17 (04) : 725 - 741
  • [7] AZD9668: Pharmacological Characterization of a Novel Oral Inhibitor of Neutrophil Elastase
    Stevens, T.
    Ekholm, K.
    Granse, M.
    Lindahl, M.
    Kozma, V.
    Jungar, C.
    Ottosson, T.
    Falk-Hakansson, H.
    Churg, A.
    Wright, J. L.
    Lal, H.
    Sanfridson, A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 339 (01): : 313 - 320
  • [8] Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase
    Miglietta, Daniela
    Carnini, Chiara
    Puviani, Veronica
    Finch, Harry
    Fox, Craig
    Fitzgerald, Mary
    Patacchini, Riccardo
    Civelli, Maurizio
    Villetti, Gino
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [9] BIOCHEMICAL AND PHARMACOLOGICAL ACTIVITIES OF SR 26831, A POTENT AND SELECTIVE ELASTASE INHIBITOR
    HERBERT, JM
    FREHEL, D
    ROSSO, MP
    SEBAN, E
    CASTET, C
    PEPIN, O
    MAFFRAND, JP
    LEFUR, G
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1992, 260 (02): : 809 - 816
  • [10] Chf6333: Pharmacological And Pharmacokinetic Characterization Of A Novel Potent Inhaled Inhibitor Of Neutrophil Elastase
    Carnini, C.
    Brogin, G.
    Patacchini, R.
    Miglietta, D.
    Stefani, M.
    Finch, H.
    Fitzgerald, M.
    Fox, C.
    Puccini, P.
    Villetti, G.
    Civelli, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195